Drug companies reach $2.15B settlement in patent-infringement case -Takeda Pharmaceutical and Pfizer will receive a total of $2.15 billion as part of a settlement reached with generic-drug manufacturers in a patent-infringement case. The damages stem from an "at-risk" launch of a generic substitute for the heartburn drug Protonix. In an at-risk launch, a generic-drug company begins selling a generic medication while patent litigation is still underway. The strategy can backfire if a drug patent is later found to be valid, which is what happened in this case. The Wall Street Journal (6/12).
Posted on: Fri, 14 Jun 2013 02:32:39 +0000